Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study ROP116991, Clinical Evaluation of 18 to 24mg/Day Ropinirole CR for Parkinson's Disease.

NCT01929317 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01929317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01929317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study ROP116991, Clinical Evaluation of 18 to 24mg/Day Ropinirole CR for Parkinson's Disease.
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Terminated
Start date
August 28, 2013
Completion date
June 9, 2015
Enrollment
81 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease